People · Operator
Named in public records as an officer, director or promoter · active 2013–2023 · Software / Tech, Other Technology, Pharmaceuticals, Biotechnology, Retailing
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Medicine Man Technologies, Inc. | — | Software / Tech | Series C | $197.1M | $214.8M | 2023 |
| Canvas Solutions Inc | — | Other Technology | Series A | $22.3M | $166.4M | 2014 |
| Titan Pharmaceuticals Inc | — | Pharmaceuticals | Series A | $15.5M | $23.0M | 2019 |
| Gemmus Pharma Inc. | — | Pharmaceuticals | Seed | $4.8M | $125.5M | 2014 |
| Soricimed Biopharma Inc. | — | Biotechnology | Seed | $2.9M | $68.5M | 2021 |
| Pattison Cole LLC | — | Retailing | Pre-Seed | $2.5M | $1.2M | 2013 |
Marc Rubin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Marc Rubin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Scott A. Smith | 1 | 8 |
| Andrew Williams | 1 | 7 |
| Wei Wang | 1 | 7 |
| Christine Jones | 1 | 5 |
| Nate Lentz | 1 | 5 |
| Mark Walsh | 1 | 4 |
| Ted Ridgway | 1 | 4 |
| Mark Angelino | 1 | 4 |
| Robert Bruce | 1 | 4 |
| James R. McNab, Jr. | 1 | 3 |
| Edward McCarthy | 1 | 3 |
| Larry Miller | 1 | 3 |
| Justin Dye | 1 | 2 |
| Andrew C. Williams | 1 | 2 |
| Leonardo Riera | 1 | 2 |
| Brad Stewart | 1 | 2 |
| Brett Roper | 1 | 2 |
| Jean-Marc Emden | 1 | 1 |
| William Guilford | 1 | 1 |
| Matt Tabrizi | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.